UTHRUnited Therapeutics Corporation
Is it growing?
Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−2.6 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 44.4% now against 47.1% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is UTHR growing?
United Therapeutics Corporation has grown revenue 14% a year over three years and 16% a year over five, with earnings per share compounding at 17%.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +16%
Revenue growth, 5-year rate · +14% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +17%
Earnings per share, 3-year rate · revenue +14% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 18
Years of annual history on file · FY2008 to FY2025, as filed
Details›
- Revenue FY2021
- $1.69B
- Revenue FY2022
- $1.94B
- Revenue FY2023
- $2.33B
- Revenue FY2024
- $2.88B
- Revenue FY2025
- $3.18B
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #2 of 41 by RyuScore